Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.37 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7325572 | 0.92 | FFAR4 (0.36) | FFAR4POLBPKMNPSR1AKR1C4 | |
| SCHEMBL14702595 | 0.88 | PKM (0.40) | FFAR4PKMNPSR1 | |
| SCHEMBL2432528 | 0.85 | FFAR4 (0.49) | FFAR4POLBPKMNPSR1AKR1C4 | |
| SCHEMBL671175 | 0.85 | MEN1 (0.38) | FFAR4PKMNPSR1 | |
| Hydrochloric Acid SCHEMBL7626508 | 0.84 | FFAR4 (0.48) | FFAR4POLBPKMNPSR1AKR1C4 | |
| SCHEMBL14907126 | 0.78 | CCR5 (0.38) | POLB | |
| SCHEMBL17269667 | 0.76 | AKT1 (0.41) | PKM | |
| SCHEMBL672668 | 0.76 | LMNA (0.44) | PKMNPSR1 | |
| SCHEMBL30888630 | 0.75 | AKT1 (0.42) | FFAR4 | |
| SCHEMBL2465219 | 0.75 | AKR1C4 (0.38) | FFAR4AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | MERCK SHARP & DOHME CORP | 2013-02-14 | — | — | US | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-6127379-A | TREATING IRRITABLE BOWEL SYNDROME, URINARY INCONTINENCE, ATRIAL ARRHYTHMIA OR STROKE | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-10-03 | — | — | US | disclosed |
| EP-0625149-A1 | BENZOPYRAN, BENZOTHIOPYRAN AND BENZOFURAN DERIVATIVES AS 5-HT4 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993016072-A1 | BENZOPYRAN, BENZOTHIOPYRAN AND BENZOFURAN DERIVATIVES AS 5-HT4 ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-19 | — | — | WO | disclosed |
| US-4329459-A | ENDOPEROXIDE CYCLOXGENASE INHIBITORS | THE UPJOHN COMPANY (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | SSTR5, SSTR2, SSTR4 | FFAR4 108/4885POLB 3734/4885SRD5A1 218/4885 |
| US-20130040978-A1 | SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS | SSTR5, SSTR2, SSTR1 | FFAR4 122/4885POLB 3584/4885SRD5A1 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.